The Mechanisms and Interventions in Health and Disease research program seeks to enhance the understanding of health and disease in the following ways:

  • researching the fundamental mechanisms of cells, biological systems and disease processes
  • translating this knowledge into the development and implementation of interventions that maintain health, treat disease and inform policy and practice for enhanced health outcomes.

Program members use fundamental basic, applied, clinical and translational research approaches.

In total, the Mechanisms and Interventions in Health and Disease Program has more than 100 staff and higher-degree research students.

The program has three main research focus areas with ten research groups, outlined here.

Associate Professor Nir Eynon researches genetics, epigenetics and molecular performance in health and disease.

Our research interests

Key areas of research expertise within the program include: 

  • biomechanics
  • cancer biology and metastasis
  • cardiovascular health and disease
  • drug design and development, immunotherapeutics and vaccine design
  • exercise science
  • genetics and epigenetics of exercise
  • immunology and regenerative medicine
  • molecular biology
  • muscle health and disease
  • nutrition in health and disease
  • structural biology (NMR, crystallography, molecular modelling)
  • therapeutic mechanisms and manual therapy
  • women’s health.

Focus areas

Our research address these areas in particular:

  • ageing
  • autoimmune diseases (multiple sclerosis, Type-1 diabetes, inflammatory bowel diseases)
  • cancer (breast, colon, ovarian, prostate, lung, leukemia) 
  • cardiovascular disease
  • enteric neuropathy 
  • hunger management 
  • lower back pain 
  • mental health
  • metabolic disorders (obesity, Type-2 diabetes, insulin resistance, stroke)
  • motor neuron disease
  • musculoskeletal disorders (muscular dystrophy, cachexia, sarcopenia, osteosarcopenia)
  • polycystic ovarian syndrome.

Professor Vasso Apostolopoulos developed the world’s first breast and ovarian cancer vaccine.

Partners, funders & collaborators

  • Australian Catholic University, Melbourne
  • Deakin University, Melbourne
  • Flinders University, Adelaide
  • Griffith University, Brisbane
  • LaTrobe University, Melbourne
  • Macquarie University, Sydney
  • Monash University, Melbourne
  • Queensland University of Technology, Brisbane
  • RMIT University, Melbourne
  • Swinburne University, Melbourne
  • University of Adelaide, Adelaide
  • University of Melbourne, Melbourne
  • University of New South Wales, Sydney
  • University of Sydney, Sydney
  • University of Southern Queensland, Brisbane
  • University of Tasmania, Hobart
  • University of Western Sydney, Sydney

  • Ahvaz Jundishapur University of Medical Sciences, Iran
  • Aristotle University, Greece
  • Guangzhou Sport University, China
  • Harvard University, USA
  • Indiana University, USA
  • Plymouth University, UK
  • Sathyabama University, India
  • The Chinese University of Hong Kong, Hong Kong
  • Tumor Immunity Medical Research Center, Seoul
  • National University, South Korea
  • University of Aalborg, Denmark
  • University of Applied Sciences Kaiserslautern, Germany
  • University Children’s Hospital Basel, Switzerland
  • University College Erasmus, Netherlands
  • University of Copenhagen, Denmark
  • University Insubria, Italy
  • University of Ioannina, Greece
  • University of Texas at El Paso, USA
  • University of North Carolina, USA
  • University of Patras, Greece
  • Universidad Rey Juan Carlos, Spain
  • University of Tubingen, Germany
  • University of Windsor, Canada
  • University of Wisconsin-Madison, USA

  • Athletics Australia, Australia
  • Austin Hospital, Australia
  • Australian Institute for Musculoskeletal Science (AIMSS), Australia
  • Baker IDI, Australia
  • Bosch Institute, Australia
  • Cardiology Clinic Skopje, Macedonia
  • Centre for Food Allergen Research, Australia
  • Cobalt Niche Ltd, Australia
  • Copenhagen University Hospital, Denmark
  • Defence, Science and Technology (DST) Group, Australia
  • Dorsa Vi Ltd, Australia
  • ELDrug S.A, Greece Florey Neurosciences Institute, Australia
  • Garvin Institute for Medical Research, Australia
  • Gencor Pacific Ltd, Hong Kong Institute for Breathing and Sleep, Australia
  • IPC Health, Germany Karolinska Institute, Sweden
  • Macfarlane Burnet Institute for Medical Research, Australia
  • Moffitt Cancer Centre, USA
  • Murdoch Children’s Research Institute, Australia
  • NewDrug S.A, Greece
  • NovoNordisk Foundation for Basic Metabolic Research, Denmark
  • NTNU: Norwegian University of Science and Technology, Norway
  • Pasteur Institute, Greece
  • Peter MacCallum Cancer Centre, Australia
  • Prolipsis Medical Centre, Greece
  • Royal Melbourne Hospital, Australia
  • Sanitarium Foods, Australia
  • SimPharma Pty. Ltd, Australia
  • SimPharma Pte. Ltd, Singapore
  • Stop the Mets Charity, Australia
  • St Vincent’s Hospital, Australia
  • St Vincent’s Institute for Medical Research, Australia
  • The Product Makers (TPM), Australia Vianex S.A, Greece
  • Victorian Institute of Sport, Australia
  • Western Health, Australia Xblades Ltd, Australia